research:treatment_pathways_in_chronic_disease_12_mos
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Last revision Both sides next revision | ||
|
research:treatment_pathways_in_chronic_disease_12_mos [2015/02/02 18:19] jduke [Code] |
research:treatment_pathways_in_chronic_disease_12_mos [2015/02/10 16:26] rkboyce [Requirements] |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Treatment Pathways in Chronic Disease (12 Months) ====== | + | ====== Early Treatment Pathways in Chronic Disease ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** The objective of this study is to characterize the prevalence of different initial treatment pathways for three chronic diseases: Hypertension, Type II Diabetes, and Depression. We will systematically summarize the treatment pathways observed among patients who have at least 12 months of continuous observation and persistent treatment following drug initiation. We will stratify the results by year to evaluate temporal trends, and will further stratify by data source to determine if treatment pathways vary by population, geography, and data capture process. | + | **Objective:** The objective of this study is to characterize the prevalence of different initial treatment pathways for three chronic diseases: Hypertension, Type II Diabetes, and Depression. We will systematically summarize the treatment pathways observed among patients who have at least **12 months** of continuous observation and persistent treatment following drug initiation. We will stratify the results by year to evaluate temporal trends, and will further stratify by data source to determine if treatment pathways vary by population, geography, and data capture process. |
| **Rationale:** While numerous treatment guidelines exist for chronic conditions, there is a paucity of data on the real-world treatment pathways that patients experience in practice. Understanding these pathways is essential for establishing context around questions of drug utilization, effectiveness, and adherence. | **Rationale:** While numerous treatment guidelines exist for chronic conditions, there is a paucity of data on the real-world treatment pathways that patients experience in practice. Understanding these pathways is essential for establishing context around questions of drug utilization, effectiveness, and adherence. | ||
| Line 30: | Line 31: | ||
| **Database Dialect:** SQL Server, Postgres, Oracle | **Database Dialect:** SQL Server, Postgres, Oracle | ||
| - | **Software:** SQL as above, R | + | **Software:** SQL as above, R >=3.1 |
| ===== Code ===== | ===== Code ===== | ||
| Line 36: | Line 37: | ||
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | [[http://forums.ohdsi.org/t/ohdsi-study-1-treatment-pathways-in-chronic-disease/112|Treatment Pathways Discussion Thread]] | + | [[http://forums.ohdsi.org/t/ohdsi-study-2-study-on-early-treatment-pathways-in-chronic-disease/273/2|Treatment Pathways Discussion Thread]] |
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
| * Optum | * Optum | ||
| + | * GE | ||
| + | * CCAE | ||
| + | * Stanford STRIDE | ||
| * Indiana Network for Patient Care | * Indiana Network for Patient Care | ||
research/treatment_pathways_in_chronic_disease_12_mos.txt · Last modified: 2017/12/14 05:55 by schuemie
Page Tools
